<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753883</url>
  </required_header>
  <id_info>
    <org_study_id>2008_024</org_study_id>
    <secondary_id>MK0653-154</secondary_id>
    <nct_id>NCT00753883</nct_id>
  </id_info>
  <brief_title>Ezetrol Post-Marketing Study</brief_title>
  <official_title>A Randomized, Open-Labeled, Parallel Group Comparison Study to Evaluate the Efficacy, Safety of Ezetimibe Alone Versus Statin in the Treatment of Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To compare the lipid lowering efficacy of adding ezetimibe to statin vs. statin alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in lipid profiles after study drug treatment.</measure>
    <time_frame>After 16 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>simvastatin 20 mg/qd for 8 weeks, and then add on ezetrol 10mg (if ldl-c . 160mg/dl) for another 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ezetrol 10 mg/qd for 8 weeks, and then add on simvastatin 20 mg qd (if ldl-c . 160mg/dl) for another 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>simvastatin 20 mg/QD for 6 Weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>MK0733</other_name>
    <other_name>ZocorÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe 10 mg/QD for 8 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Ezetrol</other_name>
    <other_name>Zetia</other_name>
    <other_name>MK0653</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men Or Women Older Than 20 And Younger Than 80 Years Of Age

          -  Willing To Follow An Ncep Therapeutic Lifestyle Changes (TLC) Or Similar
             Cholesterol-Lowering Diet For The Duration Of The Study

          -  Female Patients Receiving Hormone Therapy (Including Hormone Replacement Therapy, And
             Estrogen Antagonist/Agonist, Or Oral Contraceptives) If Maintained On A Stable Dose
             And Regimen For At Least 8 Weeks Prior To Visit 1 And If Willing To Continue The Same
             Regimen Throughout The Study

          -  Patient With Total Cholesterol Equal Or Greater Than 240 Mg/Dl Or Ldl-C Equal Or
             Greater Than 160 Mg/Dl For Primary (Heterozygous Familial And Non-Familial)
             Hypercholesterolemia And/Or Ldl-C Equal Or Greater Than 130 Mg/Dl For Secondary
             Hypercholesterolemia With Identifiable Risk Factors

          -  Patient Is Able To Discontinue Any Lipid Lowering Drugs For 6-8 Weeks Wash-Out Period
             (6 Week For Statin And 8 Week For Fibrate)

          -  Triglyceride (Tg) Concentrations Equal Or Less Than 400 Mg/Dl

          -  Liver Transaminases (Alt, Ast) Equal Or Less Than 1.5x Uln With No Active Liver
             Disease And Equal Or Less Than 1.5x Uln At Visit 2

        Exclusion Criteria:

          -  Women Who Are Pregnant Or Lactating

          -  History Of Mental Instability, Drug/Alcohol Abuse Within The Past 5 Years, Or Major
             Psychiatric Illness Not Adequately Controlled And Stable On Pharmacotherapy

          -  Patients Who Have Been Treated With Any Other Investigational Drug Within 3 Months Of
             Visit 1

          -  Patients Previously Randomized To A Study With Ezetimibe

          -  Active Liver Disease Or Impaired Liver Function Tests (Alt, Ast &gt; 1.5xuln)

          -  Impaired Renal Function ( Serum Creatinine Equal Or Greater Than 1.5 Mg/Dl Or Urine
             Protein Equal Or Greater Than 100 Mg/L) Or Nephritic Syndrome At Visit 1

          -  Unstable Angina

          -  Myocardial Infarction, Coronary Bypass Surgery Or Angioplasty Within The Previous
             Three Months Of Visit 1

          -  Uncontrolled Cardiac Arrhythmias

          -  Uncontrolled Hypertension (Treated Or Untreated) With Systolic Blood Pressure &gt; 160
             Mmhg Or Diastolic &gt; 100 Mmhg At Visit 1

          -  Poorly Controlled Diabetes Mellitus Patient. (Hba1c&gt;8.0%). If The Patient Treated With
             Md, No Any Dm Medication Will Be Change During The Study Period)

          -  Uncontrolled Endocrine Or Metabolic Disease Known To Influence Serum Lipids Or
             Lipoprotein, E.G. Hyperthyroidism (Tsh &gt; 5.5 (Iu/Ml). However, Patients Who Are On A
             Stable Therapy Of Thyroid Replacement Therapy For At Least 6 Weeks Are Eligible For
             Enrollment

          -  Patients Hypersensitive To Hmg-Coa Reductase Inhibitors Or Ezetimibe

          -  Patient Who Is Unable To Give Informed Consent (The Patient With A Legal
             Representative To Sign The Informed Consent Is Eligible To Participate The Study.)

          -  Any Condition Or Situation Which, In The Opinion Of The Investigator, Might Pose A
             Risk To The Patient Or Confound The Results Of The Study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2008</study_first_posted>
  <last_update_submitted>September 16, 2008</last_update_submitted>
  <last_update_submitted_qc>September 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Executive Vice President, Clinical and Quantitative Sciences</name_title>
    <organization>Merck &amp; Co., Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

